Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "pharma"


25 mentions found


In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Casey's General Store is a 'hidden gem', says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: PBR, Enterprise Products, Recursion Pharma, Cheniere Energy, Casey's General Store and more.
Persons: Jim Cramer Organizations: Enterprise Products, Pharma, Cheniere Energy, Casey's
Health care shouldn't be overlooked as a place to buy amid the current market turmoil, according to Jamie Cox, managing partner at Harris Financial Group. He's been particularly interested in health care — pharma more specifically — as the industry feels tailwinds from artificial intelligence and the weight-loss drug boom. "The amount of money that the health care industry is making is being completely ignored by investors," Cox told CNBC Pro. "The noise of the short-term back-and-forth ... gives you good opportunity to buy high-quality companies, while people are just selling indiscriminately." For more diversified exposure, Cox recommended the Vanguard Health Care ETF (VHT) .
Persons: Jamie Cox, Cox, He's, FactSet, That's, they're, Johnson, Eli Lilly Organizations: Harris Financial Group, Federal Reserve, pharma, CNBC, Pharma, Novo Nordisk, Novartis, Pfizer, Swiss, Novo, Vanguard Health Care Locations: U.S
Ultragenyx Pharmaceutical has several growth opportunities ahead that could lead its share price to boom over the next year, according to RBC Capital Markets. Analyst Luca Issi initiated research coverage of the pharmaceutical company, which develops treatments for rare and ultra-rare diseases, with an outperform rating and $77 price target. Ultragenyx is forecasting between $500 million and $530 million in revenue for 2024, driven by rare bone disease drug Crysvita, long-chain fatty acid oxidation disorder drug Dojolvi, as well as therapies Mepsevii and Evkeeza. The analyst is also looking ahead to Ultragenyx's treatments for Angelman syndrome, Glycogen storage disease type 1, or GSD1a, plus Wilson's disease as potential opportunities to drive up the stock. Wilson's disease is a rare genetic disorder that prevents the body from eliminating copper, which then leads it to accumulate in the liver, brain and other organs.
Persons: Luca Issi, Issi, Issi's, Issa, GSD1a Organizations: Ultragenyx Pharmaceutical, RBC Capital Markets, U.S . Food, Drug Administration
Revenue of $15.14 billion tops $14.46 billion estimate, and $2.02 in earnings per share (EPS) clears $1.66 estimate. IB revenue better than expected. UnitedHealth Group are earnings better than feared. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.
Persons: Morgan Stanley, Vimal Kapur, Evercore, Uber, Goldman, Jim Cramer's, Jim Cramer, Jim Organizations: Club, Big, WM, Bank of America, Revenues, Johnson, Pharma, Devices, UnitedHealth, Healthcare, Honeywell, Deutsche Bank, Barclays, Tyson, Intel, Qualcomm, Nvidia, Broadcom, Marvell, Texas, Technology, NXP Semiconductors, TAM, Jim Cramer's Charitable, CNBC
British techbio startup Qureight has secured $8.5 million in an oversubscribed Series A round. Launched in 2018, Qureight wants to simplify how pharma companies deal with the complex datasets often used during clinical trials. "For example, we can start to structure images of lungs using AI," said cofounder and CEO Muhunthan Thillai. The startup primarily works with pharmaceutical companies, including heavyweights such as AstraZeneca, as well as hospitals and clinical research organizations. Check out the 11-slide pitch deck used to secure the fresh funding.
Persons: Qureight, Muhunthan Thillai, Thillai, Hargreave Hale Organizations: pharma, Business, AstraZeneca, Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Playfair, Fund, Cambridge Angels Locations: Cambridge, Meltwind
Morgan Stanley raised its price target on Netflix to $700 from $600. 7:13 a.m.: JPMorgan cuts Boeing price target, but says demand should push strong long-term growth Investors shouldn't give up on Boeing as a long-term investment, according to JPMorgan. Analyst Seth Seifman lowered his price target by $20 to $210, implying 21.1% potential upside for shares of the aerospace company. He raised his target price by $14 to $62, which suggests 4.2% potential upside for DocuSign over the next year. The analyst kept his neutral rating on the stock but cut his price target by $16 to $180.
Persons: Morgan Stanley, Seth Seifman, Seifman, — Pia Singh, Evan Seigerman, Seigerman, Karl Keirstead, DocuSign, Keirstead, Itay Michaeli, Michaeli, Tesla, Elon Musk, Benjamin Swinburne, Swinburne, Wolfe, Shreyas Patil, Patil, Fred Imbert Organizations: CNBC, Netflix, Wolfe Research, JPMorgan, Boeing, Novo Nordisk, BMO Capital Markets BMO Capital, pharma, UBS, Adobe, Citi, Citi Research, Tesla, Netflix Netflix, Mobileye Locations: China, Novo, U.S, Netflix's
The National Academy of Sciences is asking a court to allow it to repurpose about $30 million in donations from the wealthy Sackler family, who controlled the company at the center of the opioid epidemic, and to remove the family name from the endowment funds. The petition filed by the Academy in Superior Court in Washington, D.C., Thursday aims to modify the terms of the donations so the institution can use them for scientific studies, projects and educational activities. The move follows a report in The New York Times last year that examined donations from several Sackler members, including an executive of Purdue Pharma, which produced the painkiller OxyContin that has long been blamed for fueling the opioid crisis that has claimed thousands of lives. “The notoriety of the Sackler name has made it impossible for the Academy to carry out the purposes for which it originally accepted the funds,” Marcia McNutt, president of the National Academy of Sciences, said in a statement released on Thursday.
Persons: Sackler, ” Marcia McNutt Organizations: National Academy of Sciences, Academy, Washington , D.C, The New York Times, Sackler, Purdue Pharma Locations: Superior Court, Washington ,, The
Bank of America reiterates Nvidia as buy Bank of America said it's sticking with the stock as a top pick. Mizuho reiterates Block as buy Mizuho raised its price target on the payment company to $106 per share from $99. Bank of America reiterates Coinbase as underperform. Bank of America reiterates Alphabet as buy Bank of America said "AI innovation [was] on display" at the company's Google Cloud Next event. " Deutsche Bank reiterates Amazon as buy Deutsche said the company is a top pick heading into earnings. "
Persons: Morgan Stanley, Piper Sandler, Tesla, Piper, Zillow, Jefferies, Mizuho, Goldman Sachs, Goldman, TD Cowen, Cowen, William Blair, Vital, Canaccord, Truist Organizations: NVIDIA, " Bank of America, Nvidia, Bank of America, Jefferies, Mizuho, SEC, Barclays, Google, Citi, Pharma, Chevron, Exxon, Vital, Argus, Motors, of America, Deutsche Bank, Amazon, Deutsche, E Corp, National, CN Locations: FCFS, Cava, CAVA, Albemarle, 1Q24, OW
"INFLATION is BACK—and RAGING!," the former president wrote in a Truth Social post. "The Fed will never be able to credibly lower interest rates, because they want to protect the worst President in the history of the Untied States!" "I'm calling on corporations, including grocery retailers, to use record profits to reduce prices," Biden said in a statement following the CPI report. "Congressional Republicans want to slash taxes for billionaires and big corporations, while helping special interests and Big Pharma raise prices. Biden has continually blamed big corporations and Republicans for the lingering high costs of living that consumers still report feeling while touting economic gains from his own policies.
Persons: Donald Trump, Joe Biden, Biden Organizations: Federal Reserve, Congressional, Big Pharma
Morgan Stanley raised its price target on Nvidia, calling for more than 15% upside going forward. — Lisa Kailai Han 5:53 a.m.: Jefferies lowers Tesla price target, cites 'self-inflicted' wounds Tesla's troubles may not be over yet, according to Jefferies. The investment firm kept its hold rating on the electric vehicle maker and lowered its price target to $165 from $185. Jefferies analyst Philippe Houchois also said Tesla is plagued by shifting product priorities. — Lisa Kailai Han 5:53 a.m.: Morgan Stanley raises Nvidia price target Nvidia has already rallied more than 72% in 2024.
Persons: Morgan Stanley, Jefferies, Patrick Cunningham, Erik Fyrwald's, Cunningham, — Lisa Kailai Han, Zillow, John Colantuoni, Colantuoni, Scott Schoenhaus, Schoenhaus, Lisa Kailai Han, Hess, Betty Jiang, CVX, Jiang, Tesla, Philippe Houchois, Joseph Moore, Moore, — Fred Imbert Organizations: CNBC, Nvidia, Citi, Management, & Biosciences, Jefferies, National Association of Realtors, Markets, GDRX, Barclays, Chevron, NVIDIA, AMD Locations: Tuesday's, China
CNN —As the first over-the-counter birth control pill in the United States hits store shelves, the company behind the product, Perrigo, is taking steps to ensure women are aware of this new contraception option. It’s a different formulation than what is in combination hormonal birth control pills, which contain both progestin and estrogen. Combined birth control pills may carry risks for people with uncontrolled hypertension or blood clot risks for smokers older than 35. Most birth control pills are up to 99% effective at preventing pregnancy if taken as instructed. “I’m always a little skeptical of Big Pharma and their partnerships, but I think the general principle of having highly effective over-the-counter birth control be over the counter, that’s empowering” she said.
Persons: “ We’re, Opill, , Colie Edison, “ We’ve, Leila Bahbah, ” Edison, “ we’re, , , , Roe, Wade, prescribers, Joe Biden, Dobbs, Dr, Sanjay Gupta, Colleen Denny, Denny, “ I’m, ” Denny Organizations: CNN, WNBA, , ESPN, US Food and Drug Administration, Jackson, Health Organization, White, Get CNN, CNN Health, NYU Langone Hospital –, Big Pharma Locations: United States, Dobbs v,
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are all the rage, and investors are noticing. Since launching in November, the Tema Obesity and Cardiometabolic ETF (HRTS) is up 24%, crushing the S&P 500's 14.8% returns over the same period. Pot and his colleagues at Tema are bullish on the weight-loss drug stocks due to the wave of demand they see coming. Novo Nordisk estimates that only 2% of obesity cases are being treated by weight-loss drugs, Pot said. 4 weight-loss drug stocks to watchPot listed two larger stocks and two smaller ones in the space.
Persons: Maurits Pot, Janus Henderson, Pot, Goldman Sachs, Geoff Meacham, Charles Barkley, Elon Musk, Whoopi Goldberg, Eli Lilly, Lilly Organizations: VanEck Pharmaceutical, Business, World Health Organization, Novo Nordisk, Bank of America, Bank, Nordisk, FDA, Amazon, Therapeutics, Zealand Pharma Locations: Tema, GLP, Danish, it's
In the hours before delivering his State of the Union speech last month, President Biden called the chief executives of General Motors and Cisco Systems to ask their advice on the state of the American economy and share how he planned to talk about it. Then he rode to Capitol Hill and, in his address, promised to raise the rate on a new minimum tax his administration has levied on big companies “so every big corporation finally begins to pay their fair share.”“I also want to end tax breaks for Big Pharma, Big Oil, private jets, massive executive pay,” Mr. Biden continued, adding: “End it now.”The sequence epitomizes Mr. Biden’s alternatively cozy and combative relationship with America’s business leaders, which has rippled through the national economy, federal policy and now the 2024 campaign for the White House.
Persons: Biden, ” “, Mr Organizations: General Motors, Cisco Systems, Capitol, Big Pharma, Big Oil, White
Yet those numbers are reversed when asked to rate the state’s economy. In Wisconsin, negative views of the national economy outweigh positive ones by 16 points, while positive views of the state economy outweigh negative ones by 17 points. Across these battleground states, 46% of registered voters said their personal financial situation is headed in the right direction. Now, more than half of registered voters in the Wall Street Journal poll of battleground states said they either strongly or somewhat approve of the job Trump did as president. Biden is neck-and-neck with Trump among registered voters in those seven swing states on the question of protecting democracy.
Persons: Joe Biden, Donald Trump, Larry Summers, Summers, Biden, Ariel Edwards, Levy, Edwards, “ People’s, , It’s, Trump, Biden’s, Joe, Jill Biden, Robert F, Kennedy Jr, “ He’s, ” Jill Biden, Will, Sen, Bernie Sanders, Sanders “, George W, – Trump’s, Bush Organizations: CNN — Voters, Wall Street, Biden, Treasury, Federal Reserve, Gallup, Journal, Street, CBS, Vermont, White, Big Pharma, Medicare, CNN, Republican, Trump, Capitol Locations: Arizona, Georgia, Michigan, North Carolina , Nevada , Pennsylvania, Wisconsin, North Carolina, brag, Iraq
James Carville said RFK Jr.'s White House bid could be more of a drag on Trump than Biden. RFK Jr. said last week that his candidacy would be a "spoiler" for both Biden and Trump. Related storiesIn recent polling of three-way matchups between Biden, Trump, and Kennedy Jr., the former president is often slightly ahead. "Our campaign is a spoiler all right," Kennedy Jr. said during an event last week welcoming Shanahan to the ticket. Carville, who warned about cracks in the Democratic Party's electoral foundation, also expressed concern about the presidential campaigns of Cornel West and Jill Stein.
Persons: James Carville, Biden, Bobby Kennedy, Trump, MSNBC's Ari Melber, , Robert F, Kennedy Jr, Donald Trump's, Kennedy, Ari Melber, Nicole Shanahan, Shanahan, New York Sen, Carville, Cornel West, Jill Stein, they're Organizations: RFK, Trump, Biden, Service, Democratic, MSNBC, Big, Big Tech, Big Pharma, New, Cornel Locations: New York
Here are Thursday's biggest calls on Wall Street: Wells Fargo reiterates Bank of America as overweight Wells Fargo raised its price target on Bank of America to $44 per share from $40. HSBC downgrades Bank of America to hold from buy HSBC downgraded Bank of America mainly on valuation. Benchmark reiterates Nvidia as buy Benchmark said it's standing by its buy rating on Nvidia. Bank of America reiterates Amazon as buy Bank of America said it's bullish on Amazon's investments in AI. "We are initiating coverage on CYBR with a Buy rating and a $317 PT."
Persons: Wells Fargo, Bernstein, it's, Goldman Sachs, Tesla, Goldman, Piper Sandler, Piper, Clark, Kimberly, Claude, Estee Lauder, BTIG, TD Cowen, Cowen, Grindr, William Blair, Bentley, Morgan Stanley, JPMorgan, KeyBanc, Oppenheimer, Monness Crespi Hardt downgrades Palantir, Palantir Organizations: Bank of America, FDIC, Apple, HSBC downgrades Bank of America, HSBC, of America, PNC, Tesla, EV, Kimberly, Nvidia, Amazon, Bentley Systems, Allstate, JPMorgan, Major Pharma, Citi, Boeing, Barclays, Meta, SNAP Locations: mkts, DraftKings
Bernie Sanders wants to make Ozempic cheaper
  + stars: | 2024-03-28 | by ( Geoff Weiss | ) www.businessinsider.com   time to read: +2 min
Sen. Bernie Sanders said the price of Ozempic is "outrageously high." A recent study found that Ozempic can be made for less than $5 per month — but it costs nearly $1,000. AdvertisementSen. Bernie Sanders is outraged by the price of Ozempic — so much that he wants to meet with the CEO of its maker, pharma giant Novo Nordisk, Bloomberg reports. Related stories"A new Yale study found that Ozempic costs less than $5 a month to manufacture," Sanders said in a statement. Novo Nordisk also spent $5 billion on R&D globally in 2023, the company said.
Persons: Sen, Bernie Sanders, , Sanders, Lars Fruergaard Jørgensen, Sanders — Organizations: Novo Nordisk's, Bloomberg, Service, pharma, Novo Nordisk, Health, Education, Labor, Yale, Nordisk Locations: Novo, GLP, Canada, Germany, U.S, America
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The condition refers to when the small blood vessels in the lungs narrow. He noted that the drug will be a "paradigm shift" for patients living with PAH. That includes reducing the risk of death or worsening of the condition by 84% compared to an existing drug alone. Those trials include late-stage studies on patients with more advanced PAH disease, and those who are within the first year after diagnosis.
Persons: Chris Schott, Eliav Barr, PAH, Barr, Merck Organizations: Merck, Drug Administration, JPMorgan, CNBC, Acceleron Pharma Locations: Rahway , New Jersey, U.S, Winrevair
But with his latest startup, Cherish Health, he's taking a different approach. To date, Cherish Health, which makes a radar-based device to detect falls in the home, has raised $26 million from these alternative sources. Cherish Health is now gearing up to raise its Series B round, targeting $30 million at a $200 million valuation. In late 2022, Cherish Health landed $5 million in Series A funding led by Alarm.com at a $45 million valuation. If Cherish Health had gone the way of traditional venture capital, Nagpal said, "we would've given up most of our value by now."
Persons: Sumit Nagpal, Nagpal, he's, we've, JP Morgan, Health's, Health, Alarm.com, consortiums, aren't Organizations: pharma, Abbott, Business, Accenture, Health, Apple, Comcast, Amazon, Cherish Health Locations: Alere, Haven, Amazon , Berkshire, Alarm.com, VCs
Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.
Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates
The "next big thing" in tech will come from sectors such as enabling tech — which includes artificial intelligence and cybersecurity — as well as healthtech, greentech and fintech, UBS said. Here are some names from UBS' list and what it says about each stock. "The medical surgical and neurological business has also returned to strong growth as the pandemic impact fades," the bank said. Broadcom : UBS says that Broadcom boasts a "market-leading" position in semiconductor design. Its greentech picks include French industrial gases and services company Air Liquide , French utility firm Engie , and German chemicals firm Wacker Chemie .
Persons: , Stryker, ASML, — CNBC's Michael Bloom Organizations: UBS, fintech, Baidu, ASML, Broadcom, 5G, Intercontinental Exchange, Mastercard, Air, Wacker Chemie Locations: Wacker
Danish pharma giant Novo Nordisk makes both Ozempic and Wegovy. The novel drugs are also boosting pharma stocks — and Denmark's economy. Advertisement"The pharmaceutical industry has been the main driving force in the Danish economy in both the fourth quarter and for the whole of 2023," the agency said. Genmab, Zealand Pharma, and H. Lundbeck are among the other big Danish pharma firms. AdvertisementSuch businesses were a rare bright spot for Denmark's economy last year because they invested in infrastructure, created jobs, and boosted manufacturing, according to Danske Bank's chief economist Las Olsen.
Persons: , it's, Las Olsen, Olsen Organizations: Danish pharma, Novo Nordisk, Service, Nordisk, Zealand Pharma Locations: Denmark, Danish, Copenhagen
Workers are having to be coached on how to behave in the office as companies implement RTO policies. More than 60% of bosses said they plan to offer etiquette training by 2024, a survey said. "Etiquette is now like a buzzword," etiquette coach Suzy Lins, the self-proclaimed Manners Maven, told Business Insider. "In our view, office etiquette training is vital, not only for newbies but for everyone on the team," Chappell said. "Certain roles require stronger communication skills," Martin, who works at a pharma company, said about the hiring process.
Persons: , Suzy Lins, Manners Maven, Mike Chappell, Chappell, Zers, Manners Maven Lins, Lins, they've, they're, Kevon Martin, he's, Martin, it's Organizations: Service, Employees, pharma
The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.
Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo
Total: 25